Maklumat tambahan indikasi untuk upload pada laman web
Year 2012
Products Approved For Additional Indication (DCA 250 – 29 MARCH 2012)

NO	PRODUCT (ACTIVE INGREDIENT)	ADDITIONAL INDICATION	MARKETING AUTHORIZATION HOLDER
1.	1.1 **Sandostatin LAR 10mg** (Octreotide 10mg) 1.2 **Sandostatin LAR 20mg** (Octreotide 20mg) 1.3 **Sandostatin LAR 30mg** (Octreotide 30mg)	➢ INDICATION: • *Treatment of patients with advanced neuroendocrine tumours of the midgut; or of unknown primary origin where non-midgut sites of origin have been excluded.* ➢ POSOLOGY: *Treatment of patients with advanced neuroendocrine tumours of the midgut; or of unknown primary origin where non-midgut sites of origin have been excluded.* • *The recommended dose of Sandostatin LAR is 30mg administered every 4 weeks. Treatment with Sandostatin LAR for tumour control should be continued in the absence of tumour progression.*	**NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.** LEVEL 15, CREST, 3 TWO SQUARE NO. 2, JALAN 19/1, 46300 PETALING JAYA, SELANGOR .
2.	**Galvus 50mg Tablet** (Vildagliptin 50mg)	➢ INDICATION: *Galvus is indicated in the treatment of type 2 diabetes mellitus:* *As monotherapy* • *in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.* ➢ POSOLOGY: • *When used as monotherapy or in dual combination with metformin or a thiazolidinedione, the recommended daily dose of vildagliptin is 100mg, administered as one dose of 50 mg in the morning and one dose of 50 mg in the evening.*	**NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.** LEVEL 15, CREST, 3 TWO SQUARE NO. 2, JALAN 19/1, 46300 PETALING JAYA, SELANGOR .